

ASX ANNOUNCEMENT

Restructuring Update & Resignation of Director

31 October 2024

Restructuring Update – business simplification program

The Board of Anagenics Limited (ASX: AN1) (**Anagenics**) provides the following further update on progress and initiatives of the strategic review and the voluntary suspension of its securities.

Business simplification and reduction of operating cost base

The Board is continuing its work to reposition the Company with a simplified business model that it believes can, with cost restructuring and the removal of legacy expenses and liabilities, deliver modest profitability, in addition to owning a suite of brands and intellectual property related royalty streams, which are separately valuable.

The disposal of the Face MediGroup business (**FMG**) announced on 2 October 2024, was a key step to reduce the Company's overheads and business complexity. The net result being the exiting of a loss-making business and the reduction of \$670,000 of liabilities.

BLC Restructure

Following an extensive review of operations, we are currently undergoing an extensive restructuring program in order to return the group to profitability. Restructuring workstreams to date include:

- Head count (including staff and contractors) reduced from 20 to 9
- Replacement of IT & ERP systems & services to more cost effective providers
- Reduction in general overhead costs including insurance & administration expenses
- In the process of exiting offices at 55 Clarence St, Sydney
- Substantial clean-up of liabilities in the balance sheet
- \$340,000 short term funding received on 4 October 2024
- Total cost reductions are expected to exceed \$1.5 million on an annualised basis, excluding the loss making FMG

Growth Initiatives for BLC include:

- Additional sales executive added to existing sales team
- New hair care brand Manda to be released in November 2024 opening up 2 new sales channels

These initiatives simplify the business without interrupting the core sales operations.

ANAGENICS

BLC Cosmetics Ltd will be managed by existing management who have been operational in the business since 2023, reporting to the Board of Anagenics.

Board Change

In addition to previously announced management changes, Karen Matthews has resigned from her position as Director of Anagenics as of 31 October 2024. Karen remains committed to advising the Board if needed to assess future strategic opportunities.

All Board members continue to provide their services on an unpaid basis.

Voluntary suspension – update

The Board is currently engaging with third parties in relation to the restructure of the BLC business, including its ongoing operations, cost base and capital requirements, and proposed funding strategies to capitalise Anagenics' simplified business (**Restructuring**).

Successful completion of the Restructuring is critical to the Anagenics' continued financial sustainability. In the Board's opinion, trading of its securities during this time is likely to materially prejudice its ability to complete the transactions critical to its sustainability.

Anagenics' suspension will remain in place until it releases a further announcement regarding the Restructuring. Anagenics is working towards finalising these matters as soon as practicable and is aiming to do so by Friday, 29 November 2024.

This announcement was authorised by the Board of Anagenics Limited.

For further information, please contact:

Sandy Beard
Chair Anagenics Ltd.

Ph: 0412 308 263

E: sandy@xvgroup.com.au

Anagenics Limited (ASX: AN1)

Anagenics is a beauty, health & wellness business growing shareholder value through the global distribution and sales of its proprietary and licensed brands of differentiated, clinically validated anti-aging solutions. BLC Cosmetics Pty Ltd is Anagenics' wholly owned subsidiary focused on sales and distribution of leading Australian and international brands of cosmetic and wellness products. For further information, please see www.anagenics.com.